The Latin America, Middle East and Africa Immune Checkpoint Inhibitors Market is expected to witness market growth of 18.7% CAGR during the forecast period (2021-2027).
Immunotherapy, in contrast to traditional cancer therapies like radiotherapy and chemotherapy, is a cutting-edge treatment that dynamically regulates the immune system to combat cancer cells in many targets and directions. Most of the effects will be considerably amplified when used in conjunction with conventional anti-tumor therapy or numerous immune-checkpoint inhibitors (ICIs), but the exact circumstance is expected to need to be researched further. Immune checkpoint inhibitors are increasingly becoming more accessible for people all over the word. The study of similar anti-tumor medications is amid progress, and the market &use of these drugs are flourishing.
Alternative cancer treatment techniques are now actively involved in slowing cancer's progression. Precision medicines are another name for these treatments. Alternative cancer therapy has recently gotten a lot of attention in the industry since these therapies use complementary and alternative techniques and approaches to prevent and treat cancer at an earlier stage.
São Paulo has been a pioneer in the use of ICIs in Brazil since 2012 when research trials were supported by clinical practice. An increase in the spending capacities of people in countries like Argentina is expected to allow the penetration of immune checkpoint inhibitors across the region. Moreover, Breast, bladder, and liver cancers are the most common malignancies in Northern Africa; prostate, lung, and colorectal cancers are the most common cancers in Southern Africa; and esophageal and cervical cancers are the most common cancers in East Africa. Prostate cancer and cervical cancer death rates have risen in Southern Africa.
According to the National Library of Medicine, population expansion and aging is expected to result in a 70% increase in new cancer occurrences by 2030. This persistent condition has coexisted in Africa with newly found communicable diseases like Malaria, Ebola, AIDS, and COVID-19.
The Brazil market dominated the LAMEA Immune Checkpoint Inhibitors Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $658.5 million by 2027. The Argentina market is exhibiting a CAGR of 19.3% during (2021 - 2027). Additionally, The UAE market is expected to showcase a CAGR of 18.4% during (2021 - 2027).
Based on Application, the market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others. Based on Type, the market is segmented into PD-1 Inhibitor, PD-L1 Inhibitor, and CTLA-4 Inhibitor. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Beigene Ltd., Shanghai Junshi Biosciences Co., Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Merck Group (Merck Sharp & Dohme Corp.), Sanofi S.A., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.
By Application
By Type
By Country: Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Immunotherapy, in contrast to traditional cancer therapies like radiotherapy and chemotherapy, is a cutting-edge treatment that dynamically regulates the immune system to combat cancer cells in many targets and directions. Most of the effects will be considerably amplified when used in conjunction with conventional anti-tumor therapy or numerous immune-checkpoint inhibitors (ICIs), but the exact circumstance is expected to need to be researched further. Immune checkpoint inhibitors are increasingly becoming more accessible for people all over the word. The study of similar anti-tumor medications is amid progress, and the market &use of these drugs are flourishing.
Alternative cancer treatment techniques are now actively involved in slowing cancer's progression. Precision medicines are another name for these treatments. Alternative cancer therapy has recently gotten a lot of attention in the industry since these therapies use complementary and alternative techniques and approaches to prevent and treat cancer at an earlier stage.
São Paulo has been a pioneer in the use of ICIs in Brazil since 2012 when research trials were supported by clinical practice. An increase in the spending capacities of people in countries like Argentina is expected to allow the penetration of immune checkpoint inhibitors across the region. Moreover, Breast, bladder, and liver cancers are the most common malignancies in Northern Africa; prostate, lung, and colorectal cancers are the most common cancers in Southern Africa; and esophageal and cervical cancers are the most common cancers in East Africa. Prostate cancer and cervical cancer death rates have risen in Southern Africa.
According to the National Library of Medicine, population expansion and aging is expected to result in a 70% increase in new cancer occurrences by 2030. This persistent condition has coexisted in Africa with newly found communicable diseases like Malaria, Ebola, AIDS, and COVID-19.
The Brazil market dominated the LAMEA Immune Checkpoint Inhibitors Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $658.5 million by 2027. The Argentina market is exhibiting a CAGR of 19.3% during (2021 - 2027). Additionally, The UAE market is expected to showcase a CAGR of 18.4% during (2021 - 2027).
Based on Application, the market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others. Based on Type, the market is segmented into PD-1 Inhibitor, PD-L1 Inhibitor, and CTLA-4 Inhibitor. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Beigene Ltd., Shanghai Junshi Biosciences Co., Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Merck Group (Merck Sharp & Dohme Corp.), Sanofi S.A., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Lung Cancer
- Bladder Cancer
- Melanoma
- Hodgkin lymphoma
- Others
By Type
- PD-1 Inhibitor
- PD-L1 Inhibitor
- CTLA-4 Inhibitor
By Country: Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Beigene Ltd.
- Shanghai Junshi Biosciences Co., Ltd.
- Bristol Myers Squibb Company
- GlaxoSmithKline PLC
- Eli Lilly and Company
- Merck Group (Merck Sharp & Dohme Corp.)
- Sanofi S.A.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Immune Checkpoint Inhibitors Market by Application
Chapter 5. LAMEA Immune Checkpoint Inhibitors Market by Type
Chapter 6. LAMEA Immune Checkpoint Inhibitors Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- AstraZeneca PLC
- Beigene Ltd.
- Shanghai Junshi Biosciences Co., Ltd.
- Bristol Myers Squibb Company
- GlaxoSmithKline PLC
- Eli Lilly and Company
- Merck Group (Merck Sharp & Dohme Corp.)
- Sanofi S.A.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
Methodology
LOADING...
